Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545747 | 0.94 | MEN1 (0.32) | — | |
| SCHEMBL29756206 | 0.94 | MEN1 (0.32) | — | |
| SCHEMBL6990034 | 0.84 | P2RY1 (0.34) | — | |
| SCHEMBL8038479 | 0.83 | AHR (0.38) | — | |
| SCHEMBL8978583 | 0.81 | NPC1 (0.35) | GPR84 | |
| SCHEMBL7562196 | 0.80 | AHR (0.36) | — | |
| SCHEMBL12347484 | 0.79 | EIF4A1 (0.35) | — | |
| SCHEMBL6992908 | 0.78 | TLR4 (0.32) | — | |
| SCHEMBL6990194 | 0.78 | KDM4E (0.33) | GPR84 | |
| SCHEMBL2612375 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2275418-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| EP-2275418-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138876-A1 | CHROMENE COMPOUND | CHRM1, CBX8, CBX7 | GPR84 1440/4885 |
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | GPR84 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.